Panacea Biotec tumbled 7.64% to Rs 215.90 after Serum Institute of India sold 0.5% stake in the company via bulk deal on Thursday.
On Thursday, 3 December 2020, Serum Institute of India sold 3.09 lakh equity shares (or 0.50% equity) of Panacea Biotec at Rs 243.32 per share via bulk deal on the NSE.
As of 30 September 2020, Serum Institute of India held 8.03% stake in the company.
On a consolidated basis, Panacea Biotec reported a net loss of Rs 19.33 crore in Q2 September 2020 as compared to a net loss of Rs 75 crore in Q2 September 2019. Net sales surged 45.4% to Rs 182.02 crore in Q2 September 2020 over Q2 September 2019.
Panacea Biotec is an innovation-led biotechnology group that focuses on discovery, development, and commercialisation of prescription medicines.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app